NASDAQ · STOCK
CSX Corporation
$49.37
52W $31.80 – $49.29
52/100
$90.47B
29.4
1.22
Price History (6M)
Executive Summary
4 analysts weighed in with 100% agreement on a bullish lean. Growth Analyst: Quarter-over-quarter growth rate is ACCELERATING, not just positive. Overall recommendation: BUY.
Executive Summary
4 analysts weighed in with 100% agreement on a bullish lean. Growth Analyst: Quarter-over-quarter growth rate is ACCELERATING, not just positive. Overall recommendation: BUY.
Bull & Bear Case
Bull Case
- Positive MACD histogram signals bullish momentum.
- Daily trend: uptrend.
- Weekly trend: uptrend.
- Daily and weekly trends are both bullish — multi-timeframe alignment, highest confidence.
- Higher Highs / Higher Lows structure confirms bullish price action.
Bear Case
- Stochastic RSI (86.5) confirms overbought conditions.
AI Investment Committee
Committee Consensus
As of July 07, 2026
Overall Committee Score
52/100
Agreement
33%
Analysts
6
Conviction
Contested
Growth Analyst
bullish
85
/ 100 · Low confidence
Strong, accelerating growth with consistent execution
+ Quarter-over-quarter growth rate is ACCELERATING, not just positive
Technical Analyst
bullish
63
/ 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
Macro Analyst
bullish
70
/ 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ Market regime is bullish (Bull market -- normal position sizing)
News Analyst
bullish
66
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.27 across 19 articles, 14d)
Technical Analysis
RSI (14)
66.7
Neutral
MACD Histogram
0.135
Bullish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Hh Hl
Bollinger %B
0.83
Inside Bands
Price vs Moving Averages
EMA 9
$48.14
Above
EMA 21
$47.43
Above
EMA 50
$46.11
Above
EMA 200
$41.08
Above
Fundamental Analysis
Valuation
43
Growth
41
Profitability
93
Financial Health
27
Valuation
P/E Ratio
29.4×
P/B Ratio
5.13×
PEG Ratio
—
Dividend Yield
1.15%
52W High
$49.29
52W Low
$31.80
Quality & Growth
ROE
2353.0%
ROA
701.0%
Gross Margin
7151.0%
Operating Margin
3345.0%
Revenue Growth YoY
-92.0%
Debt / Equity
1.43
AI Fundamental Assessment
P/E ratio of 29.4 (moderate relative to a 15-40x range); Price-to-book of 5.1x; Revenue growth (YoY) of -0.9%; EPS growth (YoY) of -2.6%; Return on equity of 23.5%; Return on assets of 7.0%; Net margin of 21.6%; Gross margin of 71.5%; Current ratio of 0.81 (tight short-term liquidity); Debt-to-equity of 1.43; Most recent quarter beat estimates by 9.2%; EPS growth accelerating (-11.4% -> +10.3% QoQ); Analyst estimates falling over recent quarters
Key Risks
- Stochastic RSI (86.5) confirms overbought conditions.
This risk summary is generated from quantitative data signals, not qualitative opinion. All investors should conduct their own due diligence. This is not financial advice.
Get the Full CSX Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →
Mobile